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Introduction: Bevacizumab plus carboplatin-paclitaxel (BCP) che-
motherapy has Food and Drug Administration approval for advanced 
nonsquamous, non–small-cell lung cancer based upon improved sur-
vival in a clinical trial. However, subgroup analyses of this and other 
studies have suggested variable results by age and gender.
Methods: Using data from four health maintenance organizations 
(HMOs) belonging to the Cancer Research Network, 1605 HMO non-
squamous, non-small-cell lung cancer patients aged younger than 21 
years, diagnosed 2002-2010, who received carboplatin-paclitaxel (CP), 
with and without bevacizumab for first-line treatment of stage IIIB/IV 
disease were identified. Patients were categorized into three groups based 
on year of diagnosis and regimen during 120 days postdiagnosis: (1) 
diagnosed 2005–2010 and received BCP; (2) 2005–2010, CP (CP2005), 
and (3) 2002–2004, CP (CP2002). Survival differences between groups 
were estimated using Cox proportional hazard models with several pro-
pensity score adjustments for demographic, comorbidity, and tumor 
characteristics. Multivariable subanalyses were also estimated.
Results: Median survival was 12.3 months (interquartile range 
[IQR], 6.0–29.1) for BCP patients versus 8.8 months (IQR, 3.7–21.3) 
for CP2005 patients and 7.5 months (IQR, 3.8–15.6) for CP2002 
patients. In the propensity score–adjusted models, BCP demon-
strated a significant survival benefit with a hazard ratio of BCP rela-
tive to CP2005 and CP2002 patients of 0.79 (95% confidence interval 
[CI], 0.66–0.94) and 0.63 (95% CI, 0.52–0.75), respectively. In the 
 multivariable-adjusted subanalyses, relative to the CP2005 cohort, 
the BCP hazard ratios for patients age less than 65 years, age 65 
years old or older, and females were 0.78 (95% CI, 0.62–1.00), 0.74 
(95% CI, 0.54–1.00), and 0.77 (95% CI, 0.58–1.00).
Conclusions: In this community-based, comparative effectiveness 
analysis, we found an overall survival benefit for adults receiving 
BCP compared with CP.
Key Words: Nonsquamous, Non-small cell, Chemotherapy, 
Comparative effectiveness, Overall survival.
(J Thorac Oncol. 2014;9: 692–701)
Nonsquamous, non–small-cell lung cancer (NS-NSCLC) accounts for more than half of lung cancers in the United 
States, and the majority of these cases are diagnosed in advanced 
stages after a surgical cure is no longer feasible.1,2 Chemotherapy 
incrementally has improved both response and survival rates in 
patients with advanced, incurable lung cancer.3 Various chemo-
therapy regimens, mostly based on  platinum-based doublets 
with and without third-generation agents, have been shown 
to increase survival by upwards of 2 months in patients with 
advanced (stage IIIB–IV) NSCLC.4 In this context, where there 
are no realistic goals of cure, the gains in survival and potential 
for palliation must be carefully balanced against the significant 
toxicities and costs of chemotherapy.
The antiangiogenic monoclonal antibody bevacizumab 
(Avastin, Genentech/Roche, San Francisco, California) was 
initially approved by the Food and Drug Administration in 
2004 for metastatic colorectal cancer. In October 2006, bevaci-
zumab received a label extension for administration in combi-
nation with carboplatin-paclitaxel (CP) for first-line treatment 
of advanced lung cancer.5 Approval was granted based on a 
randomized trial, conducted by the Eastern Cooperative 
Oncology Group (ECOG 4599) of 878 patients with advanced 
NS-NSCLC, that demonstrated a significant survival benefit 
with hazard ratio of 0.79 (95% confidence interval [CI], 0.67–
0.92) and a progression-free-survival benefit.5–7 In unplanned 
subgroup analyses, the original trial did not find a significant 
survival benefit for patients age 65 years old or older or for 
female patients.6,8,9 However, a European Union randomized 
study showed no improvement in overall survival (OS) by 
adding bevacizumab to other platinum-based therapy,10 and 
a recent study phase II study (JO19907) found that the addi-
tion of bevacizumab to first-line CP significantly improved 
progression-free survival in Japanese patients with advanced 
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nonsquamous NSCLC, but the addition of bevacizumab did 
not translate into an OS benefit.11 Moreover, a recent retrospec-
tive cohort comparative effectiveness study using Surveillance, 
Epidemiology and End Results (SEER)-Medicare linked data 
did not find a survival benefit when bevacizumab was added to 
combination CP for elderly patients with NS-NSCLC.12
Studies using the SEER-Medicare data link sug-
gest that only 25% to 38% of older patients diagnosed with 
advanced NSCLC receive chemotherapy.12–14 Given the mod-
est improvement in survival probabilities associated with most 
chemotherapy agents coupled with the associated treatment 
toxicity, treatment for advanced NSCLC may be considered a 
 “preference-sensitive” decision. However, a study examining 
the use of chemotherapy for patients with advanced NSCLC 
who receive their care in four health maintenance organiza-
tions (HMOs) that participate in the Cancer Research Network 
(CRN) found that for the years 2000–2007, 64% of patients 
age less than 65 years and 46% of patients age 65 years old 
or older received chemotherapy.15 This study also found that 
doublet regimens containing cisplatin or carboplatin plus a 
taxane (docetaxel/paclitaxel) were the most common first-line 
chemotherapy regimens across all study years, but significant 
increases were found in triplet regimen use after 2005. By 
2007,  bevacizumab-carboplatin-paclitaxel (BCP) was the most 
common triplet and comprised 11% of all first-line treatment.
U.S. studies that describe treatment patterns for patients 
younger than those captured in SEER-Medicare or for those 
that receive their care outside of a fee-for-service setting are 
lacking. While clinical trial data provide information on treat-
ment efficacy and toxicity of these agents, variation in uptake, 
use, and outcomes for patients with NSCLC has primarily been 
studied in the SEER-Medicare patient population, using data 
before 2007. HMO-based community practice comparative 
effectiveness research studies, juxtaposed relative to SEER-
Medicare studies, can provide needed data that may be more 
generalizable than clinical trial data where strict inclusion/
exclusion criteria and standardized treatment protocols limit the 
populations under study. In addition, because of the very differ-
ent financial incentives experienced by providers in the HMO 
and the fee-for-service settings, parallel analyses conducted in 
both settings may be of significant clinical and policy relevance.
By employing methods and models consistent with 
those used by Zhu et al.,12 this study complements their 
SEER-Medicare-based study and bridges the gap in the lit-
erature associated with patients across all adult ages with 
advanced NS-NSCLC who receive care in an HMO setting. 
Using data derived from the Virtual Data Warehouse (VDW) 
at four HMOs participating in the National Cancer Institute–
funded CRN (http://crn.cancer.gov/), and employing methods 
to address selection bias, we examined whether the addition 
of bevacizumab to first-line CP therapy was associated with 
a significant survival benefit for adult patients with stage 
IIIB–IV NS-NSCLC.
METHODS
Research Setting
Patients included in this study received their care at 
four nonprofit HMOs (the Colorado, Northern California, 
Northwest regions of Kaiser Permanente, and Group Health 
Cooperative). In each of these health plans, the majority of 
cancer care was delivered by salaried physicians in  plan-owned 
facilities. This study was approved by the institutional review 
boards of the four participating HMOs.
Data Sources
As described in detail elsewhere, the VDW is a standard-
ized data model that was developed for research use across the 
CRN.15,16 Within the VDW, the Virtual Tumor Registry (VTR) 
contains data consistent with the North American Association of 
Central Cancer Registries standards.17 VTR data are derived from 
manual reviews of cancer patients’ medical charts by trained 
abstractors and include coded clinical data associated with 
inpatient and outpatient events, date of diagnosis,  first-course 
definitive treatment (surgery, radiotherapy, chemotherapy, etc.), 
tumor characteristics, and patient demographic characteristics—
including race and ethnicity. VDW diagnosis and procedure 
files include coded diagnoses and procedures associated with 
inpatient and outpatient encounters or events, including can-
cer treatment-related surgery, radiotherapy, and chemotherapy 
that were extracted from electronic medical records (EMRs) 
and other claims databases. Codes were based on International 
Classification of Diseases, Ninth Revision, Clinical Modification, 
Healthcare Common Procedure Coding System, and the Fourth 
Edition of the Common Procedure Terminology codes. The 
VDW pharmacy and infusion files capture National Drug 
Code–based prescription drugs dispensed from both outpatient 
pharmacies and infusion centers. The VDW census files include 
ecological surrogates for median family income and education 
derived from mapping patients’ residential addresses to census 
data. VDW death data are derived from the tumor registries, 
membership data, state level (CA, CO, OR, WA) death datasets, 
and data from the Social Security Administration.
Study Sample
The study sample included patients identified in the 
VTR as aged 21 years and older, diagnosed with stage IIIB/
IV NSCLC between January 1, 2002, and December 31, 2010, 
and followed through December 31, 2011. Consistent with the 
criteria described by Zhu et al.,12 eligibility for these analyses 
was limited to patients with health plan enrollment at the time 
of cancer diagnosis, first cancer diagnosis, survival of at least 1 
month after cancer diagnosis, and a pathologically confirmed 
diagnosis. Patients were excluded if they were diagnosed with 
squamous cell types or if they were receiving concurrent radi-
ation and chemotherapy. Patients were followed from cancer 
diagnosis until death, health plan termination, or the end of 
the study; whichever came first.
Our previous research15 showed that use of bevacizumab 
began in 2005, after Food and Drug Administration approval 
for use in metastatic colorectal cancer, but before the 2006 
label extension for administration in combination with CP 
for first-line treatment of advanced lung cancer. Therefore, 
our primary comparison groups were patients diagnosed in 
2005–2010 who received first-line CP (CP2005) and patients 
diagnosed in 2005–2010 who received first-line BCP. Using 
methods consistent with Zhu et al.,12 we defined a second 
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control group composed of patients diagnosed in 2002–2004 
(CP2002) who received CP.12 This second control group was 
created to minimize selection bias caused by the exposure of 
patients to either BCP or CP in 2005–2010 that may have been 
based on unobserved patient characteristics associated with 
survival outcomes.
Identification of First-Line Carboplatin, 
Paclitaxel, and Bevacizumab
Eligible patients receiving first-line CP with or with-
out bevacizumab were identified using VDW pharmacy, 
procedure, and infusion files using methods described pre-
viously.15,16,18 First-line therapy was defined as the first che-
motherapy regimen identified within 120 days of cancer 
diagnosis. All chemotherapy agents administered within 8 
days of the chemotherapy start date were considered to be part 
of the same regimen. Patients with concurrent administra-
tion of chemotherapy and radiotherapy, defined as start dates 
within 14 days of each other, were excluded. Patients receiv-
ing CP or BCP as a second-line regimen were not included in 
this analysis.
Survival Outcomes
The primary outcome was all-cause mortality, defined 
as the number of months from the start of first-line chemother-
apy until death. The VDW death files for the HMOs included 
in this study captured death through December 31, 2011. 
Patients who disenrolled or were alive at the end of the study 
period were censored.
Baseline Characteristics
The VTR was used to identify the age of the patient at 
diagnosis, sex, race/ethnicity, tumor grade, and stage. The 
presence of specific comorbidities was determined using the 
Quan adaptation of the Charlson comorbidity index, modified 
to exclude cancer diagnoses.19 The algorithm was applied to 
diagnoses associated with inpatient and outpatient events that 
occurred in the 13 months prior to cancer diagnosis. Surrogate 
patient-level measures of socioeconomic status were obtained 
from VDW census files. For patients diagnosed after 2005, 
we also captured other known pretreatment negative predic-
tor factors or possible exclusion criteria for BCP treatment6 
including bleeding, thrombosis, use of anticoagulants, brain 
metastasis, and active cardiovascular disease.
Statistical Analysis
Analyses were performed comparing the BCP 
group with both the CP2005 group and the CP2002 group. 
Differences in baseline characteristics between the groups 
were evaluated using the chi-square test. Medians and inter-
quartile ranges (IQRs) of time to death were estimated using 
the Kaplan-Meier method and compared between groups with 
log rank tests.20 Given that one goal of this study was to jux-
tapose CRN VDW findings relative to those derived using 
SEER-Medicare data, we used models consistent with those 
described by Zhu et al.,12 we initially estimated unadjusted 
and multivariate-adjusted Cox proportional hazard models, 
adjusting for similar baseline characteristics, to evaluate the 
effect of the addition of bevacizumab on survival. We also 
performed several propensity score analyses to balance the 
observed characteristics of patients nonrandomly assigned 
to different treatments.21–23 Logistic regression was used to 
obtain a propensity score adjusted for age, sex, gender, health 
plan, education, American Joint Committee on Cancer stage, 
tumor grade, and comorbidity score. To adjust for the differ-
ences between groups, we estimated Cox proportional haz-
ard models that included the propensity score.24 BCP and CP 
patients were also matched 1:1 on the logit of the propensity 
score using greedy nearest-neighbor matching with a 0.02 
caliper.25,26 Lastly, a stabilized inverse probability of treat-
ment weighted (IPTW) Cox proportional hazard model was 
estimated to improve the efficiency and reduce the bias of 
unweighted estimators.21,27 These weights were then incorpo-
rated into the Cox models.
Several different multivariable subgroup analyses 
were performed by limiting the cohort to (1) patients less 
than 65 years; (2) patients 65 years and older; (3) female 
patients only, consistent with Brahmer et al.9; (4) stage IV 
patients to investigate the imbalance in stage, which was 
more prevalent in the BCP group; (5) patients with no 
comorbidities to indirectly address issues related to selec-
tion bias; and (6) patients diagnosed before 2010 to address 
any potential issues related to immortal time bias given the 
secular increase in the use of bevacizumab.28 A second set of 
propensity score models were also reestimated comparing 
the BCP group with the CP2005 group to include additional 
negative predictor factors for BCP treatment. In addition, 
models and subgroup analyses were also reestimated sepa-
rately for patients less than 65 years and patients 65 years 
and older. All analyses were performed using SAS 9.2 (SAS 
Software Inc., Cary, NC).
RESULTS
Cohort Description and Baseline Characteristics
Of the 5430 patients diagnosed with stage IIIB or IV 
NS-NSCLC between 2002 and 2010 who met the inclusion/
exclusion criteria (Figure 1), 2872 (52.9%) received identifi-
able chemotherapy and 1605 patients (55.9% of those treated) 
received first-line treatment with CP or BCP. Within this cohort, 
496 patients (31%) were diagnosed between 2002 and 2004 
and received CP (CP2002 group); 911 patients (57%) were 
diagnosed between 2005 and 2010 and received CP (CP2005 
group); and 198 patients (12%) were diagnosed between 2005 
and 2010 and received bevacizumab plus CP (BCP group). 
As noted in Table 1, relative to either CP-only group, patients 
receiving BCP were significantly younger, more likely to 
have stage IV disease, and more likely to have a well—or 
moderately—differentiated tumors. There were no signifi-
cant differences in the distribution of race/ethnicity, gender, 
comorbidities, income, and education between the BCP and 
CP groups. For the negative predictor factors that were noted 
as exclusion criteria in the original ECOG 4599 trial,6 statisti-
cally significant differences in three criteria or diagnoses were 
noted between the BCP and CP2005 groups. Specifically, the 
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BCP group had a higher proportion of patients diagnosed with 
ischemic heart disease (3.0% versus 1.1%, p = 0.05), but a 
lower proportion of patients diagnosed with atrial fibrillation 
(3.0 versus 7.0, p = 0.04) and hypertension (42.4 versus 52.0, 
p = 0.01). No differences were found for pretreatment diag-
nosis of hemoptysis, CNS metastases, history of hemorrhagic 
diathesis, coagulopathy, or therapeutic anticoagulation.
Survival Outcomes
Kaplan-Meier survival curves are shown in Figure 2. 
Crude median survival estimates by patient characteristics are 
noted in Table 2. Overall median survival was 12.3 months 
(IQR, 6.0–29.1) for the BCP patients compared with 8.8 
months (IQR, 3.7–21.3) for the CP2005 group and 7.5 months 
(IQR, 3.8–15.6) for the CP2002 group.
Consistent with the Kaplan-Meier curves in Figure 2, 
and as described in Table 3, for all adult patients, the adjusted 
Cox proportional hazards models consistent with those used 
by Zhu et al. showed a significant protective survival effect 
for patients receiving the bevacizumab combination relative to 
both the CP2005 group (HR, 0.79; 95% CI, 0.66–0.94) and the 
CP2002 group (HR, 0.63; 95% CI, 0.52–0.75). Similar esti-
mates were found for the propensity score–adjusted models. 
The protective and statistically significant survival effect of 
BCP was robust across all model specifications as compared 
to the CP2002 group. However, as compared to the CP2005 
group, the protective effect of adding bevacizumab was no 
longer statically significant for the propensity score–stabilized 
IPTW models. These findings were robust to the model speci-
fication of using only patients diagnosed before 2010 (i.e., all 
patients had the opportunity for at least 2 years of follow-up).
Controlling for demographic and clinical characteristics 
in the multivariable-adjusted Cox proportional hazards mod-
els, we also found that relative to CP2005 or CP2002, BCP 
was associated with a consistent protective effect, with hazard 
ratios of less than 1.0, in all subanalyses including those lim-
ited to age less than 65, age 65 years and older, females only, 
stage IV, and patients with no comorbidities. Specifically, 
for patients age less than 65 years, relative to CP2005 and 
CP2002, the estimated hazard ratios associated with BCP 
were 0.78 (95% CI, 0.62–1.00) and 0.62 (95% CI, 0.48–0.80). 
Similarly, for patients age 65 years and older, relative to 
CP2005 and CP2002, the estimated hazard ratios associated 
with BCP were 0.74 (95% CI, 0.54–1.00) and 0.64 (95% CI, 
0.46–0.88).
As noted in Table 4, when the propensity score models 
comparing BCP to CP2005 were reestimated to include the neg-
ative predictor factors for BCP that were noted as exclusion cri-
teria in the ECOG 4599 trial,6 the results noted above held. With 
exception of the propensity score–stabilized IPTW models, the 
FIGURE 1.  Selection of patients for lung cancer 
treatment cohort. AJCC, American Joint Committee 
on Cancer; B, bevacizumab; CP,  carboplatin-paclitaxel; 
NSCLC, non–small-cell lung cancer.
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TABLE 1.  Characteristics of IIIB/IV Nonsquamous NSCLC Patients in the Three Treatment Cohorts
Characteristics
Bevacizumab Carboplatin- 
Paclitaxel 2005–2010 (n = 198)
Carboplatin-Paclitaxel 
2005–2010 (n = 911)
Carboplatin-Paclitaxel 
2002–2004 (n = 496)
No. (%) No. (%) pa No. (%) pa
Age at diagnosis, yr
  <60 89 (44.9) 281 (30.8) <0.001 164 (33.1) 0.02
  60–64 37 (18.7) 163 (17.9) 90 (18.1)
  65–69 37 (18.7) 170 (18.7) 111 (22.4)
  70–74 20 (10.1) 143 (15.7) 63 (12.7)
  75+ 15 (7.6) 154 (16.9) 68 (13.7)
Age at diagnosis, yr
  <65 126 (63.6) 444 (48.7) <0.0001 254 (51.2) 0.003
  65+ 72 (36.4) 467 (51.3) 242 (48.8)
Gender
  Female 96 (48.5) 448 (49.2) 0.85 253 (51.0) 0.54
  Male 102 (51.5) 463 (50.8) 243 (49.0)
Race ethnicity
  White 155 (78.3) 691 (75.9) 0.43 352 (71.0) 0.06
  Hispanic <6 38 (4.2) 36 (7.3)
  Black 11 (5.6) 69 (7.6) 39 (7.9)
  Asian/Pacific Islander 22 (11.1) 94 (10.3) 53 (10.7)
  Other race <6 19 (2.1) 16 (3.2)
% College educated (census tract quintile)
  1 (lowest) 30 (15.2) 194 (21.3) 0.17 96 (19.4) 0.41
  2 50 (25.3) 176 (19.3) 96 (19.4)
  3 38 (19.2) 186 (20.4) 97 (19.6)
  4 42 (21.2) 175 (19.2) 104 (21.0)
  5 (highest) 38 (19.2) 180 (19.8) 103 (20.8)
Median income (census tract quintile)
  1 (lowest) 36 (18.2) 183 (20.1) 0.47 102 (20.6) 0.46
  2 44 (22.2) 184 (20.2) 93 (18.8)
  3 47 (23.7) 174 (19.1) 99 (20.0)
  4 38 (19.2) 186 (20.4) 98 (19.8)
  5 (highest) 33 (16.7) 184 (20.2) 104 (21.0)
Modified Charlson comorbidity score
  0 121 (61.1) 505 (55.4) 0.16 329 (66.3) 0.37
  1 49 (24.7) 227 (24.9) 112 (22.6)
  2+ 28 (14.1) 179 (19.6) 55 (11.1)
AJCC stage at diagnosis
  IIIB 30 (15.2) 189 (20.7) 0.07 135 (27.2) <0.01
  IV 168 (84.8) 722 (79.3) 361 (72.8)
Level of differentiation (tumor grade)
  Well/moderately 44 (22.2) 110 (12.1) <0.001 67 (13.5) <0.01
  Poor/undifferentiated 32 (16.2) 201 (22.1) 118 (23.8)
  Unknown 122 (61.6) 600 (65.9) 311 (62.7)
Exclusion criteria noted in the ECOG 4599 Trial6 that were captured before chemotherapy initiationb
Hemoptysis 7 (3.5) 53 (5.8) 0.20 NA NA
CNS metastases <6 <6 0.83 NA NA
History of hemorrhagic diathesis, coagulopathy, or 
therapeutic anticoagulation
<6 9 (1.0) 0.61 NA NA
Use of aspirin 6 (3.0) 43 (4.7) 0.29 NA NA
Stroke <6 41 (4.5) 0.21 NA NA
Ischemic heart disease 6 (3.0) 10 (1.1) 0.05 NA NA
(Continued)
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addition of bevacizumab again showed a statistically significant 
protective effect with the estimated hazard ratios associated 
with BCP for the multivariable-adjusted model, the propen-
sity score–adjusted model, and the propensity score matching 
model of 0.80 (95% CI, 0.66–0.98), 0.82 (95% CI, 0.66–0.999), 
and 0.63 (95% CI, 0.45–0.89), respectively.
When all multivariate and propensity score–adjusted 
models and subgroup analyses were reestimated separately 
for patients less than 65 years and patients 65 years and older, 
we found similar results (see Supplementary Tables 3 and 4, 
Supplemental Digital Content, http://links.lww.com/JTO/
A544). All hazard ratios across all models estimated were less 
than 1.0. However, we did not find a statistically significant OS 
effect for either age stratification relative to the CP2005 in any of 
the multivariate or propensity score–adjusted models. Relative 
to the earlier CP2002 group, the protective survival effect was 
statistically significant for both age stratifications in all adjusted 
models except for the propensity score–matched sample.
DISCUSSION
Using clinical data from four CRN sites, we compared 
survival outcomes for patients with advanced NS-NSCLC 
who were treated with carboplatin and paclitaxel with and 
without the addition of bevacizumab. Our findings echo the 
results of the ECOG 4599 trial, where bevacizumab was found 
to improve OS in the studied population. This study, while not 
without limitations, is an important confirmation of the origi-
nal trial findings in all adult NSCLC patients.
We believe that this study provides important evidence 
for the selected use of bevacizumab in the community setting. 
Because the benefit of adding bevacizumab in the ECOG 4599 
study was relatively modest, one could hypothesize that out-
comes in community practices, where patient selection may 
be less stringent and monitoring less frequent, that the benefit 
of bevacizumab might disappear or be diluted. To the contrary, 
our data show fairly robust benefit that closely approximates 
the survival curves seen in ECOG 4599.6
Further, this study represents another important proof 
of concept for our ability to merge chemotherapy, staging, 
and survival data from the electronic health records of a large 
HMO-based population. Inasmuch as these results approxi-
mate results seen from a large randomized controlled trial, we 
believe this validates the use of these tools for future health 
outcomes and comparative effectiveness research.
FIGURE 2.  Kaplan-Meier curves for all groups. 
BCP, bevacizumab plus carboplatin-paclitaxel; 
CP, carboplatin-paclitaxel.
Atrial fibrillation 6 (3.0) 64 (7.0) 0.04 NA NA
Angina 6 (3.0) 37 (4.1) 0.50 NA NA
Hypertension 84 (42.4) 474 (52.0) 0.01 NA NA
ap-Values for comparisons with bevacizumab-carboplatin-paclitaxel cohort.
bSpecific ICD9 diagnosis codes used are available from the author upon request.
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; ICD9, International Classification of Diseases, Ninth Revision; NA, not applicable; 
NSCLC, non–small-cell lung cancer. 
TABLE 1. Continued
Characteristics
Bevacizumab Carboplatin- 
Paclitaxel 2005–2010 (n = 198)
Carboplatin-Paclitaxel 
2005–2010 (n = 911)
Carboplatin-Paclitaxel 
2002–2004 (n = 496)
No. (%) No. (%) pa No. (%) pa
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Our findings also complement the subgroup analysis 
from ECOG 4599 and the work of Zhu et al.12 who found 
that BCP was not associated with better survival among 
 Medicare-aged patients with advanced NS-NSCLC. Although 
our estimated hazard ratios for patients age 65 years and older 
were consistently less than 1.0, our estimates did not reach 
statistical significance in all models. However, our sample 
only included 72 patients age 65 years and older who received 
bevacizumab. Consistent with the SEER-Medicare study, 
elderly patients who received BCP (versus CP) in the HMO/
CRN setting were more likely to be diagnosed with stage IV 
disease. Conversely, between-group differences in the comor-
bidity burden were not consistent between the two studies. 
Although Zhu et al. found that bevacizumab-treated patients 
were less likely to have two or more comorbidities (6.3% ver-
sus 16.3%; p < 0.001), no significant differences were found 
for elderly HMO/CRN patients receiving bevacizumab versus 
CP alone (18.1% versus 16.5%; p = 0.23). While our find-
ings are somewhat inconclusive regarding bevacizumab in 
older patients, probably due to the small sample size, they do 
suggest that in conjunction with the results from the original 
ECOG 4599 trial, the Yang et al.29 meta-analysis, and the Zhu 
et al.12 comparative effectiveness study, consideration may 
be needed when the question of whether to prescribe bevaci-
zumab in an elderly patient presents itself.
We also found a protective, and in most cases, a sig-
nificant effect in our subgroup analyses that were limited to 
females only. There are a number of possible explanations for 
the lack of efficacy for bevacizumab for females in the ECOG 
4599 study, including known and unknown baseline prog-
nostic or clinical factors (e.g., differences in hormone levels, 
smoking status, or creatinine clearance) or second-line ther-
apy.9,30,31 In addition, a recent reanalyses of the ECOG 4599 
data found that while women 60 years old or older treated with 
chemotherapy live longer than men and younger women, the 
bevacizumab survival benefit is more pronounced in men of 
any age and in women 60 years or younger.32 However, our 
findings support the current community standard practice of 
administering adjunctive bevacizumab regardless of gender.
Our findings from sensitivity analyses were robust to the 
propensity score model inclusion of known negative predic-
tive factors for BCP treatment. However, given that the overall 
outcome in CP-treated patients in our study was much worse 
than in the ECOG 4599 trial (8.8 versus 10.3 mo), coupled 
TABLE 2.  Crude Median Survival Among Patients in the Three Treatment Cohorts
Characteristic
Crude Median Survival (IQR), Months
Bevacizumab Carboplatin-Paclitaxel 
2005–2010 (n = 198)
Carboplatin-Paclitaxel 2005–2010 
(n = 911)
Carboplatin-Paclitaxel 2002–2004 
(n = 496)
Chemotherapy regimen
  Carboplatin-paclitaxel 8.8 (3.7–21.3) 7.5 (3.8–15.6)
  Beva-carboplatin-paclitaxel 12.3 (6.0–29.1)
Age at diagnosis
  <60 11.8 (5.8–25.5) 9.2 (4.1–25.1) 7.4 (3.7–15.4)
  60–64 13.8 (4.3–30.7) 6.7 (2.7–20.0) 6.3 (3.1–15.7)
  65–69 19.7 (8.9–41.2) 8.4 (3.7–19.9) 7.6 (4.3–13.3)
  70–74 9.5 (6.1–18.3) 8.1 (4.3–18.6) 8.5 (4.6–19.8)
  ≥75 7.2 (1.8–18.7) 10.7 (4.4–23.2) 8.4 (2.7–20.0)
Sex
  Female 14.4 (7.3–34.1) 10.1 (4.1–26.5) 9.2 (4.5–19.8)
  Male 9.5 (3.4–25.1) 7.6 (3.6–17.5) 6.5 (3.5–12.7)
Race/ethnicity
  Non-Hispanic White 12.9 (8.9–17.2) 8.1 (7.3–8.9) 7.4 (6.2–8.5)
  Other 12.1 (8.3–19.7) 10.8 (9.3–13.4) 8.0 (6.5–10.6)
Modified Charlson comorbidity score
  0 12.9 (6.0–27.7) 8.8 (3.8–20.7) 7.6 (3.7–16.1)
  1 12.1 (5.7–27.6) 10.1 (4.3–24.4) 6.7 (4.0–15.4)
  ≥2 13.2 (5.2–40.1) 7.6 (3.1–18.2) 9.1 (3.8–15.4)
Level of differentiation (tumor grading)
  Well/moderately 20.2 (8.1–29.2) 13.8 (5.1–38.6) 7.4 (3.8–22.1)
  Poor/undifferentiated 8.4 (3.0–34.9) 7.8 (3.7–17.5) 6.8 (3.7–16.1)
  Unknown 10.8 (5.2–25.5) 8.7 (3.6–19.6) 8.0 (3.8–15.2)
AJCC stage
  IIIB 10.8 (7.1–22.4) 12.3 (5.7–27.5) 11.5 (4.8–21.0)
  IV 12.9 (5.4–29.1) 8.0 (3.5–19.4) 6.7 (3.6–13.3)
AJCC, American Joint Committee on Cancer; IQR, interquartile range.
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with the fact that eligibility for bevacizumab itself represents 
a powerful prognostic factor for patients with NS-NSCLC,33 
limitations of this study include not being able to determine 
from the available data whether some of the improvements 
in OS seen in the BCP group should be attributed instead to 
differences in known (or unknown) but unmeasured treat-
ment and prognostic factors. Specifically, limitations of this 
study include the absence of measures including weight loss, 
ECOG performance status, biomarkers, baseline pulmonary 
function, the location or number of sites of disease, dose of 
each chemotherapeutic regimen, median number of cycles of 
each regimen, use of bevacizumab as maintenance therapy, 
second-line or salvage therapy after CP or BCP, achievement 
of parity in toxicity-related deaths between the regimens, or 
disproportionate use of other services, such as additional 
lines of therapy (i.e., pemetrexed and epidermal growth factor 
receptor (EGFR) inhibitors) and/or earlier adoption of pallia-
tive care. In addition, variation in OS may be related to stage 
migration that occurred during the study period. For example, 
because positron emission tomography scans are more able 
to find micrometastasis, and positron emission tomography 
scans have been more frequently used in clinical practice 
in recent years,34 stage-shifts between CP2002 and CP2005 
might have possibly occurred. Consequently, more minimal 
stage IV diseases may have been diagnosed in CP2005 than 
CP2002, resulting in greater improvement in the OS in BCP, 
when compared to CP2002.
As with the prior comparative effectiveness study 
employing SEER-Medicare data that were conducted by Zhu 
et al., this study has other limitations that are consistent with 
most retrospective, observational studies.35 The study was 
limited to adult insured patients who receive their care in 
TABLE 4.  Effect of Bevacizumab Added to Carboplatin and 
Paclitaxel Chemotherapy on Hazard Ratios for Overall Survival 
for All Adults with Stage IIIB/IV Nonsquamous NSCLC for 
Patients Diagnosed from 2005 to 2009
Models
Hazard Ratio (95% CI)
Bevacizumab Carboplatin-Paclitaxel 
vs. Carboplatin-Paclitaxel 2005–2010
Multivariable-adjusted modela,b 0.80 (0.66–0.98)
Propensity score–adjusted modela,c 0.82 (0.68–0.99)
Weighting (stabilized IPW)a,d 0.76 (0.55–1.05)
Matching 1:1e 0.63 (0.45–0.89)
Reestimated propensity score using exclusion criteria noted in Sandler et al.6
aSample sizes: BCP vs. CP 2005–2010 = 198 and 911.
bThe model was adjusted for age at diagnosis, sex, race/ethnicity, health plan, tumor 
grading, census tract education, modified Charlson comorbidities, AJCC stage, and 
diagnoses noted in the Sandler exclusion criteria that are noted in Table 2.
cThe propensity of receiving BCP was estimated using a multivariable logistic 
regression model that included age at diagnosis, sex, race/ethnicity, health plan, tumor 
grading, census tract education, modified Charlson comorbidities, and AJCC stage and 
diagnoses noted in the Sandler exclusion criteria noted in Table 2. The propensity score 
was then added as a predictor in the survival model.
dThe propensity score was used to create stabilized weights.
eSample sizes: BCP vs. CP 2005–2010 = 193 and 193, BCP and CP patients were 
matched based on their propensity score.
AJCC, American Joint Committee on Cancer; BCP, bevacizumab plus carboplatin-
paclitaxel; CI, confidence interval; CP, carboplatin-paclitaxel; IPW, inverse probability 
weighting; NSCLC, non–small-cell lung cancer.
TABLE 3.  Effect of Bevacizumab Added to Carboplatin and Paclitaxel Chemotherapy on Hazard Ratios for Overall Survival for 
Adults with Stage IIIB/IV Nonsquamous NSCLC
Models
Hazard Ratio (95% CI)
Bevacizumab Carboplatin-Paclitaxel vs. 
Carboplatin-Paclitaxel 2005–2010
Bevacizumab Carboplatin-Paclitaxel vs. 
Carboplatin-Paclitaxel 2002–2004
Unadjusted modela 0.79 (0.66–0.94) 0.63 (0.52–0.75)
Multivariable-adjusted modela,b 0.76 (0.63–0.92) 0.60 (0.50–0.74)
Propensity score–adjusted modela,c 0.79 (0.66–0.95) 0.64 (0.52–0.77)
Weighting (stabilized IPW)a,d 0.78 (0.56–1.08) 0.62 (0.48–0.78)
Matching 1:1e 0.70 (0.49–0.98) 0.61 (0.47–0.78)
Multivariable-adjusted subgroup analyses
  Age < 65 yrb,f 0.78 (0.62–1.00) 0.62 (0.48–0.80)
  Age ≥ 65 yrb,g 0.74 (0.54–1.00) 0.64 (0.46–0.88)
  Females onlyb,h 0.77 (0.58–1.00) 0.61 (0.46–0.82)
  Stage IVb,i 0.75 (0.61–0.91) 0.59 (0.48–0.74)
  Estimated comorbidity score of 0b,j 0.76 (0.60–0.97) 0.67 (0.52–0.85)
aSample sizes: BCP vs. CP 2005–2010 = 198 and 911, BCP vs. CP 2002–2004 = 198 and 496.
bThe model was adjusted for age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage.
cThe propensity of receiving BCP was estimated using a multivariable logistic regression model that included age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census 
tract education, modified Charlson comorbidities, and AJCC stage. The propensity score was then included as a predictor in the survival model.
dThe propensity score was used to create stabilized weights.
eSample sizes: BCP vs. CP 2005–2010 = 192 and 192, BCP vs. CP 2002–2004 = 192 and 192, BCP and CP patients were matched based on their propensity score.
fSample sizes: BCP vs. CP 2005–2010 = 126 and 444, BCP vs. CP 2002–2004 = 126 and 254.
gSample sizes: BCP vs. CP 2005–2010 = 72 and 467, BCP vs. CP 2002–2004 = 72 and 242.
hSample sizes: BCP vs. CP 2005–2010 = 102 and 463, BCP vs. CP 2002–2004 = 102 and 243.
iSample sizes: BCP vs. CP 2005–2010 = 168 and 722, BCP vs. CP 2002–2004 = 168 and 361.
jSample sizes: BCP vs. CP 2005–2010 = 121 and 505, BCP vs. CP 2002–2004 = 121 and 329.
AJCC, American Joint Committee on Cancer; BCP, bevacizumab plus carboplatin-paclitaxel; CI, confidence interval; CP, carboplatin-paclitaxel; IPTW, inverse probability of 
treatment weighted; NSCLC, non–small-cell lung cancer.
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four HMOs located in the western United States. Although 
this cohort may not be representative of all adult NS-NSCLC 
patients in the United States, relative to the sample of clinical 
trial participants, it is likely to better reflect the characteristics 
of patients receiving care in community practices. In addition, 
with the exception of tumor registry data, all diagnostic data 
used in this study were derived from coded medical recorded 
and claims data, not manual chart abstraction.
In conclusion, our study supports the existence of a 
survival benefit associated with use of bevacizumab among 
NS-NSCLC in adult patients, regardless of gender. However, 
this was an observational study, not a replication of the origi-
nal clinical trial. Bevacizumab is a very expensive drug, with 
known toxicities and variable response rates. Additional anal-
yses need to be conducted to examine the impact of specific, 
treatment-related toxicities resulting in hospital events and 
deaths. In addition, future research should include the linkage 
of patient-reported preference and outcome data to detailed 
treatment and survival data.
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